Healthcare

HEALWELL AI Highlights Clinical-AI Research Across Multiple Diseases

HEALWELL AI announced international presentations on real-world evidence and clinical AI, including an AI tool for identifying possible cardiac amyloidosis patients.

HEALWELL AI was named to TIME’s World’s Top HealthTech Companies of 2026 and announced 12 real-world-evidence and clinical-AI presentations scheduled for international conferences. The presentations cover multiple medical areas, including inflammatory bowel disease, cardiac care, menopause-related symptoms, and dermatology. One highlighted cardiac application, AccelerATTR, uses AI-enabled identification of potential transthyretin amyloidosis patients in cardiac clinics. The company’s conference activity illustrates how clinical AI is being evaluated through real-world data and disease-specific workflows rather than only through technical benchmarks. The announced work spans meetings in Vienna, Nashville, Ottawa, and San Diego, reflecting international interest in applying AI and analytics to clinical populations. The programs include treatment persistence, healthcare use, and identification of patients who may otherwise be missed. Such applications could support earlier referral, improve population stratification, and help researchers understand how treatments perform in routine care. The announcement is not a report of regulatory approval or broad deployment of the tools. It instead shows a healthcare-technology company using scientific conferences to present evidence and research findings. The emphasis on real-world evidence is significant because healthcare organizations increasingly require proof that AI systems improve clinical decisions, patient identification, or care management in operational settings.

Original source: The Globe and Mail

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI